ArticleTechnology in cancer research & treatment
Prognostic Factors and Radiotherapy Benefit in pT3N0M0 Rectal Cancer: A Retrospective Analysis.
Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IntroductionRecurrence-related risk factors and the clinical value of adjuvant radiotherapy for stage IIA (pT3N0M0) rectal cancer (RC) remain controversial. This study aimed to explore prognostic factors for disease recurrence in patients with pT3N0M0 RC and screen for subgroups most likely to benefit from postoperative radiotherapy-based regimens.Materials and MethodsWe retrospectively enrolled patients with stage IIA rectal cancer who received radical resection between 2017 and 2023. All participants were divided into three groups according to postoperative treatment: surgery alone (S), surgery plus chemotherapy (S+CT), and surgery plus radiotherapy-based therapy (S+RT based). We collected clinicopathological characteristics, details of postoperative adjuvant therapy, and follow-up data on tumor recurrence. Disease-free survival (DFS) was calculated accordingly. Univariate and multivariate analyses were used to screen independent prognostic factors for recurrence. Subgroup and interaction analyses were further performed to determine factors associated with favorable responses to radiotherapy.ResultsA total of 114 patients with pT3N0M0 RC were included. 37 patients had disease progression during follow-up. Local recurrence rates differed significantly across the three groups (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.